Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright

Jasper Therapeutics (NASDAQ:JSPR - Free Report) had its price objective decreased by HC Wainwright from $60.00 to $40.00 in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Jasper Therapeutics' FY2029 earnings at ($10.81) EPS.

JSPR has been the subject of a number of other research reports. JMP Securities reiterated a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday. Royal Bank of Canada cut their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a report on Thursday. Finally, BMO Capital Markets started coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $67.75.

Jasper Therapeutics Price Performance

NASDAQ JSPR traded up $0.06 during mid-day trading on Friday, hitting $7.05. The stock had a trading volume of 2,449,654 shares, compared to its average volume of 1,818,043. The firm's 50 day moving average is $21.37 and its 200 day moving average is $20.27. The stock has a market capitalization of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a twelve month low of $6.57 and a twelve month high of $31.01.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JSPR. Bank of New York Mellon Corp purchased a new position in shares of Jasper Therapeutics during the 2nd quarter worth $740,000. Rhumbline Advisers acquired a new position in Jasper Therapeutics in the second quarter valued at about $300,000. American Century Companies Inc. boosted its stake in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company's stock worth $322,000 after buying an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter valued at about $59,000. Finally, Fernwood Investment Management LLC increased its position in shares of Jasper Therapeutics by 6.9% during the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock valued at $995,000 after acquiring an additional 3,427 shares during the last quarter. Institutional investors and hedge funds own 79.85% of the company's stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.